argenx (ARGX) Stock Forecast & Price Target

argenx is supported by a clear commercial and clinical inflection from Vyvgart/Vyvgart Hytrulo, with FDA approvals in December 2021, 2022, and 2024 expanding the franchise from gMG to CIDP and strengthening convenience through the subcutaneous formulation. The positive Phase 3 ALKIVIA readout, including a 15.4-point TIS improvement at 52 weeks in the combined population and statistically significant IMNM efficacy, suggests a meaningful launch opportunity in diseases still dominated by corticosteroids, immunosuppressants, and IVIG, where physicians expect efgartigimod use in roughly 26% of eligible DM patients and 24% of eligible IMNM patients within 12 months. Its appeal is further reinforced by a pipeline that extends into primary immune thrombocytopenia, thyroid eye disease, Sjogren's Disease, and FB102, giving argenx multiple shots at durable growth beyond its current approved indications.

argenx is exposed to significant clinical, regulatory, and commercial risk because its lead assets, including efgartigimod and ARGX-117, may fail in current or future trials or face approval delays from the FDA and foreign regulators. Competitive pressure is also a major concern, as autoimmune and oncologic markets are increasingly crowded and larger rivals may have superior R&D and commercial resources, limiting differentiation for Vyvgart, Vyvgart Hytrulo, and the pipeline. Although funds should be adequate for lead development programs, the company may still need additional equity financing to complete development, creating dilution risk for existing shareholders.